Deep Genomics

AI-driven drug discovery and development

Toronto, Ontario, Canada

About Deep Genomics

Deep Genomics focuses on drug development in the biotechnology sector by utilizing artificial intelligence to explore RNA biology and discover potential therapies for genetic conditions. The company's main product, the AI Workbench, employs data-driven predictions to identify new drug targets. This tool has evolved over time, with the latest version, AI Workbench 3.0, set to enhance its capabilities in targeting complex genetic diseases. Deep Genomics serves a diverse clientele, including pharmaceutical companies and research institutions, and generates revenue through the development and licensing of its AI Workbench. The goal of Deep Genomics is to accelerate the drug discovery process and improve treatment options for patients suffering from genetic disorders.

Toronto, CanadaHeadquarters
2014Year Founded
$230.3MTotal Funding
SERIES_CCompany Stage
AI & Machine Learning, BiotechnologyIndustries
51-200Employees

Benefits

Company Equity
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Professional Development Budget

Risks

Increased competition from companies like Insitro and Recursion Pharmaceuticals.
Rapid technological advancements may render current AI Workbench obsolete.
Ethical concerns and regulatory scrutiny could delay product development timelines.

Differentiation

Deep Genomics uses AI to unravel RNA biology for drug development.
The AI Workbench identifies novel drug targets and therapeutic candidates.
BigRNA model advances RNA disease mechanism discovery and candidate therapeutics.

Upsides

AI integration with CRISPR allows precise gene editing and therapeutic development.
AI-driven platforms optimize clinical trial designs, reducing costs and time to market.
AI identifies novel biomarkers, expanding target discovery capabilities.

Funding

Total raised$230.34 M
Latest valuation$900.00 M
StageSERIES_C